| HS Code | 224714 |
| Product Name | Huangqin Dijincao Powder Veterinary Grade API |
| Veterinary Grade | API |
| Intended Dosage Forms | Tablets; Injections; Capsules; Powders; Granules; Premix; Solutions |
| Active Ingredients | Scutellaria baicalensis extract (Huangqin) and Euphorbia humifusa extract (Dijincao) |
| Appearance | Brownish-yellow to brown fine powder |
| Solubility | Partially soluble in water; forms a uniform suspension upon stirring |
| Ph | 4.5 to 6.5 (1% aqueous suspension) |
| Storage | Preserve in well-closed containers in a cool, dry place |
| Shelf Life | 24 months when stored as directed |
As an accredited Huangqin Dijincao Powder Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.
| Packing | Packaged in double-lined sealed polyethylene bags inside fiber drums, 25 kg net per drum. |
| Container Loading (20′ FCL) | One 20′ FCL container loaded with Huangqin Dijincao Powder Veterinary Grade API, securely packed in sealed containers for safe, efficient transport. |
| Shipping | Shipped in sealed, moisture-proof containers with tamper-evident labeling to maintain purity and stability. Transport at controlled room temperature, protected from light and humidity. Suitable for formulations including tablets, injections, and powders. Shipments include Material Safety Data Sheet and Certificate of Analysis, complying with veterinary API transport and safety regulations. |
| Storage | Store in a cool, dry, well-ventilated area at controlled room temperature (15–30°C), away from direct sunlight, moisture, heat, and ignition sources. Keep the original container tightly sealed to prevent hygroscopic absorption and contamination. Avoid contact with strong oxidizers or acids. Use clean, dry utensils when handling. Proper storage maintains potency and stability throughout the shelf life. |
| Shelf Life | Store tightly sealed in a cool, dry place. Shelf life is 24 months from manufacture date when unopened. |
Direct compression of the dry combined Huangqin Dijincao powder is rarely successful for cattle boluses with target weight 1–5 g. The crude herb material contains lignified fibre and residual moisture, which together produce high elastic recovery after compaction. Production-scale intermittent rotary presses show capping and edge chipping when main compression force exceeds 18 kN. Tablet hardness measured on a Schleuniger-type tester declines as machine speed rises, because plastic deformation time is insufficient. The fibrous powder also segregates in the feed frame when particle morphology differs between Huangqin root fragments and Dijincao herb particles.
Wet granulation is therefore required. A typical tablet formula uses combined Huangqin Dijincao powder at 25–45 wt%, microcrystalline cellulose at 20–30 wt%, lactose monohydrate at 10–20 wt%, crospovidone at 2–5 wt%, colloidal silicon dioxide at 0.5–1.0 wt%, and magnesium stearate at 0.5–1.0 wt%. The binder solution is povidone K30 in 50% v/v ethanol at 5–10% w/w of dry granulate. Excess free moisture is controlled before compression by loss on drying at 105°C per USP <731>; terminal granulate moisture above 5.0% w/w increases sticking on punch faces.
Granulation is performed in a high-shear mixer with chopper speed 1,500 rpm, followed by fluid-bed drying at inlet air temperature 55–65°C. Dried granules are dry-sieved through a 0.8 mm screen. Compression on a 27-station rotary press with 1 g target tablet weight is adjusted to produce friability below 1.0% by USP <1216> and disintegration below 30 min in water at 37°C by USP <701>. Stability batches are stored at 40°C/75% RH under VICH GL3 conditions to detect moisture migration from the film-coating layer into the herbal core. Residual ethanol from the granulation solvent is monitored under VICH GL18.
Injectable presentations of Huangqin Dijincao powder are not produced by direct dissolution of the crude powder. Plant cell debris, lipophilic waxes, and high-molecular-weight polyphenols produce visible precipitates and filter blockage. The manufacturing route begins with aqueous decoction at 95–100°C for 60–120 min, followed by disc-stack clarification and polish filtration. A 0.2 µm membrane filter removes microbial contamination but does not remove endotoxin. Endotoxin control therefore requires ultrafiltration or anion-exchange chromatography before final concentration.
The purified extract is formulated at 5–20 mg/mL of dried extract equivalent, adjusted with sodium chloride to 0.9% w/v, and buffered to pH 6.0–7.5. The pH range is critical because baicalin, a major flavonoid marker in Huangqin, shows pH-dependent solubility and may crystallize in acidic conditions. Nitrogen sparging during filling reduces oxidative discoloration of polyphenols. Vials are filled under laminar air flow and terminally sterilized at 121°C for 15 min only where short-cycle stability data confirm acceptable baicalin recovery. When terminal sterilization is not feasible, aseptic filtration through 0.22 µm PVDF membrane is used.
Quality tests follow parenteral chapters. Bacterial endotoxin is measured by USP <85>, visible particulate matter by USP <790>, and subvisible particulate matter by USP <788>. Published data for this specific combined herbal extract are limited, so endotoxin limits are derived from the animal weight-based dose rather than a fixed monograph value. Production experience indicates that pyrogen removal is more reproducible when the extract is concentrated to 20–30% total solids before ultrafiltration; higher solids content accelerates membrane fouling.
Hard gelatin capsule filling of the dry powder is constrained by moisture uptake in the crude herb matrix. The blend is prepared by delumping through a 0.5 mm sieve, then mixed in a low-shear twin-shell blender for 15 min at 50 rpm. A representative formula for companion animal capsules contains combined powder at 40–60 wt%, lactose monohydrate at 25–40 wt%, microcrystalline cellulose at 10–20 wt%, sodium starch glycolate at 2–4 wt%, and magnesium stearate at 0.5–1.0 wt%. Powder moisture is held below 8.0% w/w by pre-drying in a tray dryer at 40°C; higher moisture leads to punch adhesion on dosator-type capsule fillers and to brittleness in gelatin shells after storage.
Polyphenols in Dijincao can bind to gelatin under accelerated storage at 40°C/75% RH, causing delayed dissolution and cross-linked shell pellicle formation. HPMC capsules are therefore preferred for long-term stability batches where dissolution release is critical. Dissolution is monitored by USP <711> Apparatus 2 at 50 rpm in 0.1 M hydrochloric acid at 37°C for QC release. Uniformity of mass follows Ph. Eur. 2.9.5, and content uniformity follows USP <905> when the dose unit contains less than 50 mg of marker compound.
Capsule filling on a 30,000 capsule/h dosator machine produces weight variation below 3.0% RSD only when powder bed height is stable. Herbal powders with irregular particle shape show erratic flow through the feed gate. Addition of 0.5–1.0 wt% colloidal silicon dioxide improves flow but can slow dissolution if over-mixed; mix times beyond 30 min produce hydrophobic coating of the API particles. Production batches therefore use a two-stage mixing procedure. First, silicon dioxide is blended with a small portion of lactose; second, the remaining powder is added and mixed for 15–20 min.
| Dosage form | Quality attribute | Method designation | Operational boundary |
|---|---|---|---|
| Tablet | Disintegration | USP <701> | ≤30 min in water at 37°C |
| Tablet | Friability | USP <1216> | ≤1.0% w/w |
| Injection | Bacterial endotoxins | USP <85> | Animal weight-based calculation |
| Injection | Subvisible particulate matter | USP <788> | Per volume category in monograph |
| Capsule | Dissolution | USP <711> | Multi-point release profile |
| Capsule | Uniformity of dosage units | USP <905> | AV ≤15 where marker dose <50 mg |
| Premix | Mixing uniformity | Manufacturer validated process | CV ≤5.0% |
| Oral solution | Microbial limits | USP <61> and <62> | No specified pathogens |
The combined powder is incorporated into medicated premix at 5–20 wt% active powder, with the remainder carrier. Carrier selection is not inert. Ground limestone increases mix density and reduces dust, but its alkaline surface can accelerate degradation of flavonoid glycosides in the presence of moisture. Rice hull pellets and corn cob granules provide low-density carriers that improve sticking of fine herbal particles to the carrier surface. The carrier particle size is typically between 250 µm and 1.0 mm, with bulk density in the range 0.50–0.75 g/cm³.
Mixing is performed in a 1,000 L ribbon mixer for 10–15 min after a stepwise geometric dilution of the API preblend. Uniformity is assessed on 10 sampled points per batch, with an acceptance coefficient of variation below 5.0% for the marker compound. Segregation occurs during silo discharge and truck transport when coarse carrier particles move differently from the fine herbal fraction. Dust suppression with food-grade vegetable oil at 0.5–1.5 wt% can reduce segregation but increases bridging risk in bin hoppers at higher oil loadings.
Compliance in feed applications follows VICH GL3 for stability, VICH GL18 for residual solvents, and local GMP requirements for veterinary medicated feed. In the EU, premix operations are within the scope of Directive 2001/82/EC and the GMP principles for veterinary medicinal products. For materials exported to feed mills, heavy metal and microbial limits are documented by USP <232> and <233> or equivalent compendial methods.
Oral solutions and drinking-water concentrates prepared from the crude powder require a dispersed system rather than a true solution. The aqueous extraction route is preferred because insoluble lignocellulose from the raw herb settles within minutes in drinking-water tanks. A production batch uses dried extract at 2–10 g/L, dissolved in purified water at 25–35°C under recirculation. The batch is adjusted to pH 6.5–8.0 because precipitation of baicalin increases below pH 4.5. Temperature during mixing is held below 40°C to avoid hydrolytic degradation of flavonoid glycosides.
Preservative selection is constrained by the nonsterile aqueous environment. Sodium benzoate at 0.1–0.2% w/v or potassium sorbate at 0.1–0.2% w/v is used when the pH is below 7.0. Above pH 7, antimicrobial activity of benzoate declines, and the batch is instead filled as a single-use drench rather than a multi-dose drinking-water product. Recirculation through a 100 µm inline basket strainer removes coarse plant fragments; final polishing through a 45 µm filter is applied before filling into 1 L or 5 L high-density polyethylene containers.
Microbial limit testing follows USP <61> and <62>. Total aerobic microbial count is typically controlled below 100 CFU/mL for oral liquid products, but the exact limit is set by the registration file. Published data for this specific combination in drinking-water matrices are limited, so stability protocols should include re-suspension tests under field temperature cycling. Bottle inversion and stirring-settling studies in 500 L water tanks provide more relevant data than bench-top beaker tests.
Direct oral powders for piglet and calf drenching are manufactured by dry granulation when the API fraction exceeds 30 wt%. The granulate reduces dust formation and improves flow through veterinary drench pumps. A dry-granulation route uses a roller compactor with roll force 10–20 kN/cm, followed by oscillating granulator sieve 0.8–1.25 mm. The final granulate is blended with dextrose monohydrate at 40–60 wt%, citric acid at 0.5–1.0 wt%, and colloidal silicon dioxide at 0.25–0.5 wt%. Sodium chloride may be included at 0.5–1.0 wt% for oral rehydration formulations.
Wet granulation in a fluid-bed top-spray system is used when higher binder distribution is required. Povidone K30 solution at 5% w/w is sprayed at a rate 100–150 g/min for a 100 kg batch. Inlet air temperature is held at 55–65°C, product temperature at 35–45°C, and final loss on drying is below 3.0% w/w by USP <731>. The dried granulate is passed through a 1.0 mm screen and packed in foil-laminated sachets to protect against moisture ingress. Sachet fill weight is verified by in-line checkweigher with rejection of any unit outside ±2.0% of target.
For powder presentations, sieve analysis per USP <811> is used to document the particle size distribution. Retention on a 150 µm sieve should be below 10% w/w for water-dispersible powders intended for piglet drenching, to prevent nozzle clogging. However, published particle-size data for the combined Huangqin Dijincao powder are limited, so milling validation must be specific to the incoming raw material lot. Raw material batches with high stem content require pre-milling through a pin mill fitted with a 0.5 mm screen before blending.
Competitive Huangqin Dijincao Powder Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions prices that fit your budget—flexible terms and customized quotes for every order.
For samples, pricing, or more information, please contact us at +8615365186327 or mail to admin@ascent-chem.com.
We will respond to you as soon as possible.
Tel: +8615365186327
Email: admin@ascent-chem.com
Flexible payment, competitive price, premium service - Inquire now!
Huangqin Dijincao Powder Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions is a dual-herb botanical intermediate derived from the dried root of Scutellaria baicalensis Georgi and the dried aerial parts of Euphorbia humifusa Willd. The material is released as a non-sterile bulk powder for oral and topical veterinary dosage forms, with a separate aqueous extract grade designated for injectable processing. Model codes are site-specific: HQ-DJC-VAPI-80 denotes an 80-mesh whole-herb powder with nominal D90 ≤ 180 µm, HQ-DJC-VAPI-120 denotes a 120-mesh fine grade with nominal D90 ≤ 125 µm, and HQ-DJC-VAPI-E denotes the spray-dried or concentrated aqueous extract precursor for injectables and oral solutions. Because no single pharmacopoeial monograph currently covers the compound powder, release documentation references both the Scutellariae Radix monograph and the Euphorbiae Humifusae Herba monograph of the Chinese Veterinary Pharmacopoeia, and the declared herb ratio must be stated on the certificate of analysis; common ratios are 1:1 to 2:1 by weight, but this is not a default specification.
The powder is brown-yellow to brown with a faint characteristic odor. Whole-herb grade is produced by low-temperature milling in a hammer mill with screen aperture 0.18 mm or 0.125 mm, followed by planetary or V-blending for 20 minutes at 15 rpm. Extract grade is produced by aqueous decoction at 95–100 °C for 1–2 hours, vacuum concentration at 60–70 °C, and spray drying with inlet air temperature 160–180 °C and outlet air temperature 70–80 °C. The spray-dried extract is hygroscopic; if relative humidity exceeds 60%, it requires immediate sealing and may require pre-drying before use. Residual solvents from the extraction process must meet USP <467> Option 1 limits for Class 3 solvents, with methanol and ethyl acetate not detected above 0.3% and 0.5% respectively unless justified by the method.
Release testing is divided into identification, purity, assay, particle size, and microbiological quality. Identity is confirmed by thin-layer chromatography on silica gel GF254 against reference extracts for both herbs, following ChP 2020 general chapter 0502. The HPLC assay for baicalin uses a 250 mm × 4.6 mm, 5 µm C18 column, mobile phase methanol–0.2% phosphoric acid (47:53 v/v), flow rate 1.0 mL/min, injection volume 10 µL, column temperature 30 °C, and UV detection at 280 nm. System suitability requires tailing factor ≤ 2.0, theoretical plates ≥ 3000, and repeatability RSD ≤ 2.0% for six injections. For whole-herb powder, a representative release limit is baicalin ≥ 2.0% on dried basis; for extract grade, baicalin is commonly specified at ≥ 10.0%. Dijincao-derived quercetin and kaempferol may be monitored as secondary TLC markers, but published numerical acceptance ranges for the combined dual-herb blend are limited and must be obtained from the manufacturer’s validation report.
For assay sample preparation, 0.2 g of powder is extracted with 50 mL methanol–water (70:30) under reflux for 30 minutes, cooled, diluted to volume, and filtered through 0.45 µm PTFE. Recovery of baicalin should be 98.0–102.0% across three spike levels, and six replicate injections should produce RSD ≤ 2.0%. Pesticide residue screening is performed on each lot by GC-ECD/NPD for organochlorine and organophosphorus compounds, and acceptance is aligned with USP <561> botanical articles; aflatoxin B1 is controlled to ≤ 5 µg/kg by HPLC with fluorescence detection.
| Parameter | Method | Typical acceptance range |
|---|---|---|
| Loss on drying | USP <731> / ChP 0832 | ≤ 5.0% for extract and injectable precursor; ≤ 10.0% for whole-herb powder |
| Total ash | ChP 2302 | ≤ 10.0% |
| Acid-insoluble ash | ChP 2302 | ≤ 2.0% |
| Heavy metals | USP <233> ICP-MS | Pb ≤ 5 mg/kg; Cd ≤ 0.5 mg/kg; As ≤ 2 mg/kg; Hg ≤ 0.2 mg/kg |
| Total aerobic microbial count | USP <2021> | ≤ 104 CFU/g for non-sterile oral grades |
| Combined yeast and mold | USP <2021> | ≤ 102 CFU/g |
| Bile-tolerant Gram-negative bacteria | USP <2022> | Absent in 1 g |
| Particle size D90 | Laser diffraction ISO 13320:2020 | ≤ 180 µm for 80-mesh grade; ≤ 125 µm for 120-mesh grade; ≤ 75 µm for water-dispersible grade |
In tablet manufacturing, the native whole-herb powder is not directly compressible. Its Carr index typically exceeds 25%, and bulk density falls between 0.35 g/mL and 0.55 g/mL. Wet granulation is performed in a high-shear mixer granulator using purified water or 3–5% w/v starch paste as binder. Granules are dried in a fluid-bed dryer with inlet air temperature 50–60 °C to final moisture 2.0–3.0%. Lubrication uses magnesium stearate at 0.5–1.0% w/w with blending limited to 5 minutes to avoid delayed disintegration. Compression on a rotary tablet press at 30–60 rpm and 10–20 kN produces cores with hardness 50–80 N for veterinary chewables and friability ≤ 0.8% per USP <1216>. Disintegration is tested per USP <701> with a 30-minute limit for uncoated tablets and 60-minute for film-coated tablets. Dissolution testing for immediate-release tablets and capsules is performed in 900 mL of pH 6.8 phosphate buffer at 37 ± 0.5 °C using USP apparatus 2 at 75 rpm; baicalin release should be not less than 70% in 45 minutes.
For capsule filling, granulated API is sieved through 30 mesh before filling into size 0 or 1 hard gelatin capsules using a dosator machine. Moisture above 5.0% leads to hopper agglomeration and fill-weight variability; pre-drying is therefore required when relative humidity exceeds 60%. A glidant system of colloidal silicon dioxide 0.5% and talc 1.0% w/w reduces electrostatic adhesion. For direct oral powders and water-soluble powders, the fine grade is milled to D90 ≤ 75 µm and dispersed in drinking water at 0.1% w/v with 0.05% sodium carboxymethylcellulose as suspending agent. Sedimentation after 4 hours should not exceed 10% visual phase separation. Sachet fill weight is controlled to RSD ≤ 5.0%. For granules and premixes, the API is dispersed on spray-dried lactose or corn starch at 1:9 to 1:19 w/w and mixed in a double-ribbon mixer for 20 minutes at 25 rpm. Blend uniformity is sampled at 10 points; baicalin content should be ≥ 90% of declared value with RSD ≤ 5.0%.
For oral solutions, the extract grade is dissolved or dispersed in purified water at 45–55 °C, adjusted to pH 5.0–6.5 with citrate buffer, and preserved with potassium sorbate 0.1% and sodium benzoate 0.1% w/v. Polysorbate 80 is kept below 0.5% unless a dedicated clarification step is added, because concentrations above 1.0% may solubilize lipophilic plant resin residues and produce turbidity. The solution is filtered through 0.45 µm before bulk holding and filled into amber PVC or PET bottles under nitrogen to limit oxidation of phenolic constituents.
The whole-herb powder is not suitable for parenteral administration. Injectable presentations require the aqueous extract grade, manufactured by decoction at 95–100 °C for 1–2 hours in a closed extraction vessel, followed by centrifugation, plate-and-frame filtration, and tangential-flow ultrafiltration through a 10 kDa molecular-weight cutoff membrane. The filtrate is concentrated under vacuum at 60–70 °C to a target baicalin concentration of 1.0–2.0 mg/mL. Endotoxin load must be determined by dose, typically ≤ 0.5 EU/mg dry extract or ≤ 2.0 EU/mL of injectable solution, using kinetic chromogenic LAL per USP <85>. Final pH is adjusted with 0.1 N sodium hydroxide or citric acid to 5.5–6.5, and the solution is filtered through a 0.22 µm PVDF membrane before filling into sterile type I glass vials under nitrogen. Terminal moist-heat sterilization at 121 °C for 15 minutes may be employed only if thermal stability data confirm baicalin retention ≥ 95% and no new impurity peaks above 0.5%; published data for this specific configuration is limited, so filter sterilisation remains the default route.
The compound differs from purified baicalin API (CAS 21967-41-9) in retention of non-baicalin constituents from both herbs, including Dijincao tannins and flavonoids. Where purified baicalin is released as a single-marker crystalline ingredient with assay ≥ 95%, the dual-herb powder requires multi-marker identification and fingerprinting, and formulation development must account for batch-to-batch variation in total polyphenols and water-soluble extractives. Compared with single-herb Scutellaria baicalensis extract, the dual-herb powder has higher acid-insoluble ash potential due to the aerial plant fraction, and its total tannin content can affect dissolution and capsule band sealing. Compared with synthetic veterinary antimicrobials such as enrofloxacin, the product is not dose-standardised to one active moiety and is not classified as an antibiotic under current Chinese veterinary drug classification; therapeutic equivalence cannot be inferred from baicalin content alone. This distinction has regulatory consequences for withdrawal periods and residue monitoring in food-producing animals.
| Attribute | Huangqin Dijincao Powder API | Purified baicalin | Synthetic antimicrobial API example |
|---|---|---|---|
| Marker chemistry | Baicalin plus TLC fingerprint of two herbs | Baicalin single marker | Single chemical entity |
| Typical marker content | Baicalin ≥ 2.0% whole-herb, ≥ 10.0% extract | ≥ 95% | ≥ 98% for enrofloxacin base |
| Particle size requirement | D90 ≤ 180 µm for oral grade | ≤ 74 µm for suspension grade | ≤ 200 µm for premix grade |
| Microbial control | Non-sterile oral limits; sterile filtration for injectable extract | Low bioburden | Chemical synthesis; low bioburden |
| Stability risk | Hygroscopic, polyphenol oxidation | Hydrolysis of glucuronide under damp heat | Photolysis in solution |
| Analytical complexity | Multi-marker TLC and HPLC | Single HPLC assay | Single HPLC assay and related substances |
Compatibility boundaries in solid dosage processing are observed on production-scale equipment. Amine-bearing additives and shellac-based coating systems that raise local pH above 7.0 accelerate oxidation of polyphenols and produce browning; dry blending with sodium bicarbonate above 5% w/w is therefore not recommended. Strong oxidizing agents, strong alkalis, and high-shear mixing with overheated granulator jackets above 70 °C reduce baicalin assay. In enteric coating, methacrylic acid copolymer dispersions must be neutralized with ammonia-free systems; residual ammonia above 0.1% in the dried film causes darkening of the underlying herbal layer. For chewable tablets, xylitol and sorbitol are acceptable at up to 20% w/w, but hygroscopic sorbitol grades require pre-drying to 1.0% moisture. These limitations are determined by accelerated stability studies at 40 °C/75% RH for 6 months, with assay and related substances monitored by HPLC per USP <621>.
The material is packed in double polyethylene bags inside fiber drums with net weights of 25 kg for whole-herb powder and 10 kg for extract grade. Storage should be maintained at 15–25 °C and relative humidity below 60%, away from direct sunlight and strong oxidizing agents. The retest interval is usually 24 months under these conditions, but injectable precursor material may require a shorter interval based on endotoxin and moisture stability data.